Human monoclonal antibodies for discovery, therapy, and vaccine acceleration.
Human monoclonal antibodies for discovery, therapy, and vaccine acceleration. Curr Opin Immunol. 2019 Aug 23;59:130-134 Authors: Andreano E, Seubert A, Rappuoli R Abstract Screening of single B cells from convalescent or vaccinated people allows the discovery of novel targets for infectious diseases and rapid production of engineered human monoclonal antibodies (mAbs) that can prevent or control infections by passive immunization. Here we propose that the development of human mAbs can also significantly accelerate vaccine development by anticipating some of the key biological and regulatory questions. PMID: 31450054 [PubMed - as supplied by publisher]
Date: Friday, 02 28, 2020; Speaker: Anna P. Durbin, Professor, Johns Hopkins University; Building: Building 40; CR1201/1203
Date: Tuesday, 05 12, 2020; Speaker: Hans Langedijk; Building: Building 40; CR1201/1203
Date: Tuesday, 05 26, 2020; Speaker: Peter Palese, Ph.D. , Professor, Ichan School of Medicine at Mount Sinai; Building: Building 40; CR1201/1203
Date: Tuesday, 06 02, 2020; Speaker: Andrea L. Cox, M.D., Ph.D., Professor, Johns Hopkins Medicine; Building: Building 40; CR1201/1203
Date: Tuesday, 10 27, 2020; Speaker: Erol Fikrig, M.D., Professor, Yale School of Medicine; Building: Building 40; CR1201/1203
Date: Friday, 01 31, 2020; Speaker: Mattia Bonsignori, M.D. , Associate Professor, Duke Human Vaccine Institute, Duke University Medical Center; Building 33; Room 1N09
Date: Tuesday, 02 11, 2020; Speaker: Tony Moody, M.D., Associate Professor of Pediatrics, Duke Human Vaccine Institute; Building: Building 40; CR1201/1203
In this report, we present a case of ADEM associated with optic neuritis presenting alongside two potential triggering factors: chikungunya virus infection and yellow fever immunization.
Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by recurrent bacterial infections and defined by reduced levels of IgG, IgA, and/or IgM, insufficient response to polysaccharide vaccination, and an abnormal B-cell immunophenotype with a significantly reduced fraction of isotype-switched memory B cells. In addition to this infectious phenotype, at least one third of the patients experience autoimmune, autoinflammatory, granulomatous, and/or malignant complications. The very heterogeneous presentation strongly suggests a collection of different disease entities with somewhat different patho...
Johnson &Johnson's chief scientist told CNBC that the company started developing a shot from scratch last week, and that he is 'pretty confident' that it will work, despite the long vaccine pipeline.